Quarterly report pursuant to Section 13 or 15(d)

Related Party Matters (Details)

v3.23.3
Related Party Matters (Details)
3 Months Ended 4 Months Ended 9 Months Ended
Mar. 01, 2023
USD ($)
Feb. 28, 2023
USD ($)
May 18, 2022
USD ($)
shares
Mar. 01, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Apr. 30, 2021
agreement
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Related Party Transaction [Line Items]                    
Other current liabilities         $ 921,549     $ 921,549   $ 1,366,994
Exclusive Sponsored Research Agreement | EHBE                    
Related Party Transaction [Line Items]                    
Prepaid expense - related party         0     0   50,000
Research and development expense         0 $ 50,000   50,000 $ 150,000  
ESRA Agreement, Screening Platform For Anteroposterior Ocular Diseases                    
Related Party Transaction [Line Items]                    
Research and development expense         0 39,167   47,000 167,000  
Other current liabilities         0     0   7,835
Accounts payable         0     0   47,001
ESRA Agreement, Screening Platform For Anteroposterior Ocular Diseases | EHBE                    
Related Party Transaction [Line Items]                    
Annual retainer amount       $ 190,500            
Consulting Agreement                    
Related Party Transaction [Line Items]                    
Accounts payable         0     0   12,511
Dr. Avtar Dhillon | Independent Contractor Agreement                    
Related Party Transaction [Line Items]                    
Accrued expense under agreement         0 0   0 87,926  
Prepaid expense - related party                   $ 8,056
Independent Contractor Services Agreement | Jim Heppell                    
Related Party Transaction [Line Items]                    
Initial term of research agreement (in years)     1 year              
Monthly fee     $ 6,300              
Increase In monthly fee     $ 16,600              
Termination payment $ 74,700                  
Granted (in shares) | shares     16,000              
Collaborative Research Agreement | Emerald Health Biotechnology Espana, S.L.U.                    
Related Party Transaction [Line Items]                    
Number of collaborative research agreements | agreement             2      
Collaborative Research Agreement | Emerald Health Biotechnology Espana, S.L.U. | Emerald Health Research, Inc                    
Related Party Transaction [Line Items]                    
Subsidiary ownership (as a percent)             100.00%      
Consulting Agreement | Dr. Avtar Dhillon                    
Related Party Transaction [Line Items]                    
Fees incurred under agreement         $ 0 $ 47,590   $ 0 $ 8,595  
Consulting Agreement | Immediate Family Member of Management or Principal Owner                    
Related Party Transaction [Line Items]                    
Annual rate per hour   $ 73                
Termination notice period (in days)   15 days